(Press-News.org) Most patients with ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) who have an implantable cardioverter-defibrillator (ICD) now live more than seven years and those ICD patients with hereditary heart disease can live for decades, based on a scientific paper that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3.
With ICM, the left ventricle of the patient's heart pumps blood poorly due to coronary artery disease. With DCM, the heart has become weakened and enlarged, and cannot pump blood efficiently. Therefore, these conditions often require ICDs to improve blood flow and prevent sudden cardiac death.
"These patients commonly contend with sudden cardiac death and heart failure," according to lead author Robert Hauser, MD, a cardiologist at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis. However, the long-term survival of these patients treated with contemporary ICDs is "unknown due to the lack of clinical studies that followed these patient populations after implantation," Hauser says, and this information would be valuable for improving ICD therapy.
Therefore, Hauser and his colleagues retrospectively assessed survival for ICD patients implanted at Minneapolis Heart Institute® between 2000 and 2009.
Between 2000 and 2009, 1,555 patients (mean age: 64.9 years; gender: 75.2 percent male) received initial single chamber (18.5 percent), dual chamber (42.2 percent) or cardiac resynchronization (39.3 percent) ICDs.
The average survival for these patients was seven years, and individuals with hereditary heart disease lived much longer since they were generally younger at the time of implantation.
"We were pleased to discover how long these patients were living," Hauser said. "Because these patients are living this long, it has significant implications for how long the devices need to last. Typically, ICDs last between four to six years, but these findings indicate that the devices require long-lived batteries."
The researchers concluded that their findings, which were consistent across all ICD manufacturers, also underscore the need for long-lived ICD pulse generators and leads.
"Contemporary ICDs need to be flexible and durable enough to adapt to the evolving clinical needs of the patient who is living longer," Hauser says.
###
Minneapolis Heart Institute®
The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.
Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation is dedicated to creating a world without heart disease through groundbreaking clinical research and innovative education programs. MHIF's mission is to promote and improve cardiovascular health, quality of life and longevity for all.
Are ICDs up to par with patients living longer?
2011-04-04
ELSE PRESS RELEASES FROM THIS DATE:
Chest pain med is effective for refractory angina, but adherence problematic
2011-04-04
Ranolazine (Ranexa, Gilead) is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3.
Patients with refractory angina, who have chronic chest pain but are not candidates for revascularization, have limited therapeutic options and significant limitations in their quality of life, the study authors wrote. Conversely, patients with chronic angina ...
Hartford Students Receive a $78,000 Gift of Success - The Birch Group, LLC and TTI Performance Systems Donate Their Skills and Talent to the Academy
2011-04-04
Each of the 400 students at Hartford Public High School Engineering and Green Technology Academy received a key to success in the form a DISC Behavioral and Workplace Motivator Assessment courtesy of Bill Bonnstetter, CEO and founder of TTI Performance Systems, Ltd. in Scottsdale, AZ and John Birch, founder and president of The Birch Group, LLC, a management consultant firm based in New Britain, CT. TTI Performance Systems generously provided the assessments and The Birch Group administered and coordinated the reports as well as provided training to the students. The value ...
Protocol-driven heart attack care proves effective and contagious
2011-04-04
The implementation of acute heart attack or ST-elevation myocardial infarction (STEMI) guidelines, protocols and standing orders in Minnesota community hospitals without cardiac catheterization labs has dramatically improved since 2003, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3.
Since the 1990s, the American College Cardiology (ACC)/American Heart Association (AHA) STEMI guidelines recommended that all hospitals develop protocols and standing orders (reperfusion strategy, ...
Serum test could identify lung cancer in people who never smoked
2011-04-04
ORLANDO, Fla. — A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
While lung cancer has long been linked to smoking, approximately one-fourth of patients with lung cancer have never smoked. Researchers are working on ways to identify the presence of lung cancer in these patients.
Charlie Birse, Ph.D., associate director of product development at Celera Corporation, and colleagues are investigating ...
Protein test detects early-stage, asbestos-related pulmonary cancer
2011-04-04
ORLANDO, Fla. — Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
In a blinded test performed under the auspices of the National Cancer Institute's Early Detection Research Network Biomarker Discovery Lab, the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about ...
Breast milk may provide a personalized screen of breast cancer risk
2011-04-04
ORLANDO, Fla. — Breast cancer risk can be assessed by examining the epithelial cells found in breast milk, according to preliminary study results presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
This screening method has the potential to provide a personalized assessment of breast cancer risk, said lead researcher Kathleen F. Arcaro, Ph.D., associate professor of veterinary and animal sciences at the University of Massachusetts Amherst. Given that roughly 80 percent of women give birth, this screen would also cover a large percentage of the female population. ...
Nicotine does not promote lung cancer growth in mouse models
2011-04-04
ORLANDO, Fla. — Nicotine at doses similar to those found in most nicotine replacements therapies did not increase lung cancer tumor incidence, frequency or size, according to results of a mouse study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
"If you take our data and combine it with epidemiological data from Europe, even in people who quit smoking and maintain the use of nicotine replacement therapy for months or years, there does not appear to be increased lung cancer incidence," said Phillip A. Dennis, M.D., Ph.D., senior investigator at ...
Aspirin may lower the risk of pancreatic cancer
2011-04-04
ORLANDO, Fla. — The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Xiang-Lin Tan, Ph.D., M.D., a research fellow at Mayo Clinic in Rochester, Minn., said the findings from this large collaborative study are preliminary and do not encourage widespread use of aspirin for this purpose.
"The results are not meant to suggest everyone should start taking aspirin once monthly to reduce their risk ...
Lung cancer risk rises in the presence of HPV antibodies
2011-04-04
ORLANDO, Fla. — Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer. These results, which were presented at the AACR 102nd Annual Meeting 2011, held April 2-6, indicate that HPV antibodies are substantially increased in people with lung cancer.
Devasena Anantharaman, Ph.D., postdoctoral fellow in the Genetic Epidemiology Group at the IARC in Lyon, France, and ...
MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men
2011-04-04
ORLANDO, FL (April 4, 2011) – Prostate cancer is the second leading cause of cancer-related death among American men. Yet population-wide screening programs have not reduced the number of deaths from the disease. By focusing screening programs on the men who are at greatest risk for aggressive disease or diagnosis at a young age, researchers think they could improve mortality rates and personalize the screening approach. For that reason, scientists have been looking for genetic markers to help them identify exactly which men are at high risk and require regular screening. ...